Cardiff Oncology, Inc. (CRDF)
NASDAQ: CRDF · Real-Time Price · USD
1.730
0.00 (0.00%)
At close: Mar 25, 2026, 4:00 PM EDT
1.740
+0.010 (0.58%)
Pre-market: Mar 26, 2026, 8:38 AM EDT
Cardiff Oncology Revenue
In the year 2025, Cardiff Oncology had annual revenue of $593.00K, down -13.18%. Cardiff Oncology had revenue of $243.00K in the quarter ending December 31, 2025, with 60.93% growth.
Revenue (ttm)
$593.00K
Revenue Growth
-13.30%
P/S Ratio
199.45
Revenue / Employee
$19,129
Employees
31
Market Cap
118.27M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 593.00K | -90.00K | -13.18% |
| Dec 31, 2024 | 683.00K | 195.00K | 39.96% |
| Dec 31, 2023 | 488.00K | 102.00K | 26.42% |
| Dec 31, 2022 | 386.00K | 27.00K | 7.52% |
| Dec 31, 2021 | 359.00K | -7.00K | -1.91% |
| Dec 31, 2020 | 366.00K | 121.37K | 49.61% |
| Dec 31, 2019 | 244.63K | -133.69K | -35.34% |
| Dec 31, 2018 | 378.33K | -127.08K | -25.14% |
| Dec 31, 2017 | 505.40K | 124.33K | 32.63% |
| Dec 31, 2016 | 381.07K | 68.26K | 21.82% |
| Dec 31, 2015 | 312.81K | 32.63K | 11.65% |
| Dec 31, 2014 | 280.18K | 20.93K | 8.07% |
| Dec 31, 2013 | 259.25K | -191.16K | -42.44% |
| Dec 31, 2012 | 450.40K | 192.71K | 74.78% |
| Dec 31, 2011 | 257.70K | -273.63K | -51.50% |
| Dec 31, 2010 | 531.33K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Karyopharm Therapeutics | 146.07M |
| Black Diamond Therapeutics | 70.00M |
| Spero Therapeutics | 40.55M |
| Sangamo Therapeutics | 32.88M |
| Innate Pharma | 14.84M |
| Equillium | 4.39M |
| Artiva Biotherapeutics | 251.00K |
| Inovio Pharmaceuticals | 65.34K |
CRDF News
- 6 days ago - Cardiff Oncology to Host Key Opinion Leader Discussion Focusing on First-Line RAS-mutated Metastatic Colorectal Cancer - GlobeNewsWire
- 7 days ago - Cardiff Oncology to Present Preclinical Data with Highly Specific PLK1 Inhibitor Onvansertib at the 2026 AACR Annual Meeting - GlobeNewsWire
- 27 days ago - Cardiff Oncology to Participate in Three Upcoming Investor Conferences - GlobeNewsWire
- 4 weeks ago - Cardiff Oncology Reports Full Year 2025 Results and Provides Business Update - GlobeNewsWire
- 5 weeks ago - Cardiff Oncology to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference - GlobeNewsWire
- 2 months ago - Cardiff Oncology Stock Plunges After Sudden Leadership Change, Narrowed Trial Focus - Benzinga
- 2 months ago - Cardiff Oncology, Inc. (CRDF) Discusses Management Transition and Onvansertib Phase II Data Update in RAS-Mutated mCRC Transcript - Seeking Alpha
- 2 months ago - Cardiff Oncology Announces Positive Update from its Randomized Phase 2 Trial of Onvansertib in First-line RAS-mutated mCRC - GlobeNewsWire